Latest Conference Articles

Educated Patient® Multiple Myeloma Summit Basics of Myeloma Panel: March 12, 2022

Educated Patient® Multiple Myeloma Summit Basics of Myeloma Panel: March 12, 2022

April 1st 2022, 1:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Saad Z. Usmani, MD, MBA, with Carlyn Rose Tan, MD; Neha S. Korde, MD; and Kenny Capps answer audience Q&A during the CURE Educated Patient Multiple Myeloma Summit.

Educated Patient® Multiple Myeloma Summit Risk Stratification for the Newly Diagnosed Presentation: March 12, 2022

Educated Patient® Multiple Myeloma Summit Risk Stratification for the Newly Diagnosed Presentation: March 12, 2022

March 31st 2022, 1:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Dr. Carlyn Rose Tan, an assistant attending in myeloma service at Memorial Sloan Kettering Cancer Center, present on risk stratification for newly diagnosed patients.

Educated Patient® Multiple Myeloma Summit MGUS/Smoldering Myeloma Presentation: March 12, 2022

Educated Patient® Multiple Myeloma Summit MGUS/Smoldering Myeloma Presentation: March 12, 2022

March 30th 2022, 1:00pm

Educated Patient® Multiple Myeloma Summit: March 12, 2022

Watch Dr. Neha S. Korde, an assistant professor in multiple myeloma service in the Division of Hematology at Memorial Sloan Kettering Cancer Center, present on MGUS/smoldering myeloma.

Intravenous and Direct-to-Abdomen Chemotherapy Plus Avastin Lead to Similar Outcomes in Advanced Ovarian Cancer

Intravenous and Direct-to-Abdomen Chemotherapy Plus Avastin Lead to Similar Outcomes in Advanced Ovarian Cancer

March 23rd 2022, 7:00pm

SGO Annual Meeting on Women's Cancer

There were no major differences in survival when comparing intravenous and intraperitoneal chemotherapy plus Avastin in patients with advanced ovarian cancer, research shows.

Treatment With Novel Drug Induces Promising Response Rates in Ovarian Cancer Subgroup

Treatment With Novel Drug Induces Promising Response Rates in Ovarian Cancer Subgroup

March 22nd 2022, 3:00pm

SGO Annual Meeting on Women's Cancer

“These results position mirvetuximab soravtansine to become a practice-changing, biomarker-driven, standard-of-care treatment option for patients with (high folate receptor-alpha)-positive, platinum-resistant ovarian cancer,” noted one of the study authors.

Zejula-Avastin Combo Improves Outcomes, With ‘No Impact on Quality of Life’ in High-Risk Ovarian Cancer

Zejula-Avastin Combo Improves Outcomes, With ‘No Impact on Quality of Life’ in High-Risk Ovarian Cancer

March 22nd 2022, 12:30pm

SGO Annual Meeting on Women's Cancer

Zejula plus Avastin led to promising progression-free survival rates with no new side effects for patients with newly diagnosed, advanced ovarian cancer.

PSMA-Targeted Treatment Improves Bone-Related Pain in Metastatic, Castration-Resistant Prostate Cancer

PSMA-Targeted Treatment Improves Bone-Related Pain in Metastatic, Castration-Resistant Prostate Cancer

March 7th 2022, 4:00pm

ASCO Genitourinary Symposium

Patients treated with Lutetium-177 PSMA-617 tended to experience improvements in quality of life related to the aches and pains that can come from bone metastases.

Drug Duo Sparks Encouraging Outcomes in Treatment of Clear Cell Kidney Cancer

Drug Duo Sparks Encouraging Outcomes in Treatment of Clear Cell Kidney Cancer

March 1st 2022, 10:00pm

In a recent clinical trial, treatment with Bavencio plus Inlyta produced promising outcomes in the presurgical treatment of patients with non-metastatic, clear cell renal cell carcinoma.

Cabometyx Before Surgery May Shrink Tumors With No Disease Progression in Advanced Kidney Cancer

Cabometyx Before Surgery May Shrink Tumors With No Disease Progression in Advanced Kidney Cancer

February 22nd 2022, 8:00pm

Treatment with Cabometyx before surgery in patients with advanced renal cell carcinoma, a type of kidney cancer, may provide benefits, although further research is required before a decision is made about its role in presurgical treatment.

Updated Results on Lenvima-Keytruda Combo ‘Still Encouraging’ for Patients With Advanced Kidney Cancer, Expert Says

Updated Results on Lenvima-Keytruda Combo ‘Still Encouraging’ for Patients With Advanced Kidney Cancer, Expert Says

February 22nd 2022, 4:41pm

ASCO Genitourinary Symposium

Although the data failed to identify a predictive biomarker in patients with advanced kidney cancer, an expert from Memorial Sloan Kettering Cancer Center in New York notes that the results indicate that no one should be excluded from receiving Lenvima plus Keytruda.

Immunotherapy Agent Misses Study Survival Goal in Advanced Penile Cancer

Immunotherapy Agent Misses Study Survival Goal in Advanced Penile Cancer

February 22nd 2022, 2:08pm

ASCO Genitourinary Symposium

Tecentriq failed to meet the progression-free survival goal in a trial analyzing the immunotherapy agent in advanced squamous cell carcinoma of the penis.

Even in the Prescence of Health Complications and Other Medications, Nubeqa Maintains Safety, Efficacy in Prostate Cancer Treatment

Even in the Prescence of Health Complications and Other Medications, Nubeqa Maintains Safety, Efficacy in Prostate Cancer Treatment

February 21st 2022, 8:00pm

ASCO Genitourinary Symposium

Patients with nonmetastatic castration-resistant prostate cancer who were taking other medications or had health complications still derived a survival benefit from treatment with Nubeqa, research showed.

Fotivda Boosts Survival and Has ‘Interesting’ – and Tolerable – Safety Profile for Kidney Cancer Treatment

Fotivda Boosts Survival and Has ‘Interesting’ – and Tolerable – Safety Profile for Kidney Cancer Treatment

February 21st 2022, 4:00pm

ASCO Genitourinary Symposium

Fotivda – a TKI drug that was approved last year – not only improved survival outcomes, but was also very tolerable in terms of side effects for patients with metastatic renal cell carcinoma.

Prehab, Rehab May Improve Health and Well-Being in Patients Receiving CAR-T Cell Therapy

Prehab, Rehab May Improve Health and Well-Being in Patients Receiving CAR-T Cell Therapy

February 15th 2022, 8:00pm

Prehab and rehab may help patients with cancer who are receiving CAR-T cell therapy return to health or even better, but there are still challenges.

Three-Drug Combo Proves Efficacious, Safe in Unresectable Liver Cancer

Three-Drug Combo Proves Efficacious, Safe in Unresectable Liver Cancer

February 7th 2022, 4:38pm

Treatment with a combination of PD-1 inhibition, minimally invasive chemotherapy and Lenvima improved outcomes for patients with unresectable liver cancer compared to PD-1 inhibition and Lenvima alone.

New Drug Combination May Improve Outcomes in Unresectable Liver Cancer

New Drug Combination May Improve Outcomes in Unresectable Liver Cancer

January 27th 2022, 10:00pm

ASCO Gastrointestinal Cancers Symposium

An expert from Memorial Sloan Kettering Cancer Center in New York discusses the promising findings from a study that analyzed tremelimumab plus Imfinzi for unresectable hepatocellular carcinoma, and outlines side effects patients should discuss with their doctor.

Adagrasib Confers High Response Rates in Several Gastrointestinal, Pancreatic Tumors

Adagrasib Confers High Response Rates in Several Gastrointestinal, Pancreatic Tumors

January 26th 2022, 10:00pm

ASCO Gastrointestinal Cancers Symposium

Single-agent adagrasib was associated with encouraging treatment responses in patients with previously treated non-colorectal gastrointestinal tumors and pancreatic ductal adenocarcinoma.

Oral Antimetabolite After Surgery Associated With Survival Benefit in Biliary Tract Cancer

Oral Antimetabolite After Surgery Associated With Survival Benefit in Biliary Tract Cancer

January 26th 2022, 8:00pm

ASCO Gastrointestinal Cancers Symposium

Patients with biliary tract cancer achieved a better survival outcome after receiving treatment with an oral antimetabolite following surgical resection than patients who only were treated with surgery.

Keytruda Plus Mektovi and Avastin Associated With Survival Benefit in Metastatic Colon Cancer

Keytruda Plus Mektovi and Avastin Associated With Survival Benefit in Metastatic Colon Cancer

January 25th 2022, 4:17pm

ASCO Gastrointestinal Cancers Symposium

A group of patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer experienced responses to treatment with Keytruda plus Mektovi and Avastin.

Blood Test Results May Identify Which Patients With CRC May Benefit From Post-Surgical Chemotherapy

Blood Test Results May Identify Which Patients With CRC May Benefit From Post-Surgical Chemotherapy

January 25th 2022, 2:11pm

ASCO Gastrointestinal Cancers Symposium

The use of a ctDNA assay could help determine which patients with colorectal cancer may benefit most from chemotherapy after surgery.

Gut Microbiome Makeup May Help Predict Skin-Related Immunotherapy Side Effects in Patients With Gastric Cancer

Gut Microbiome Makeup May Help Predict Skin-Related Immunotherapy Side Effects in Patients With Gastric Cancer

January 24th 2022, 4:00pm

ASCO Gastrointestinal Cancers Symposium

Patients with gastric cancer who present with certain bacteria in their gut were found to be more likely to experience skin-related side effects from Opdivo treatment, research showed.

Patients With Unresectable Liver Cancer May Have a ‘Promising and Tolerable’ Treatment Option With Combination Therapy

Patients With Unresectable Liver Cancer May Have a ‘Promising and Tolerable’ Treatment Option With Combination Therapy

January 24th 2022, 2:21pm

ASCO Gastrointestinal Cancers Symposium

The use of a non-invasive procedure combined with Lenvima plus Tyvyt demonstrated safe and effective results in patients with liver cancer not eligible for surgical resection.

Lenvima May Offer Survival Benefit With Manageable Side Effects in Recurrent HCC After Liver Transplantation

Lenvima May Offer Survival Benefit With Manageable Side Effects in Recurrent HCC After Liver Transplantation

January 23rd 2022, 3:00pm

ASCO Gastrointestinal Cancers Symposium

Researchers observed this benefit in recurrent HCC after liver transplantation, which represents a patient population often excluded from clinical trials due to potential organ rejection.

Frontline Lenvima Provided Survival Benefit for Patients With Liver Cancer

Frontline Lenvima Provided Survival Benefit for Patients With Liver Cancer

January 22nd 2022, 3:00pm

ASCO Gastrointestinal Cancers Symposium

Treating patients with liver cancer initially with Lenvima instead of the standard of care was associated with a survival benefit, according to recent research.

Minimally Invasive Procedure Combined with Lenvima and Checkpoint Blockade Shows Promise in Unresectable Liver Cancer

Minimally Invasive Procedure Combined with Lenvima and Checkpoint Blockade Shows Promise in Unresectable Liver Cancer

January 21st 2022, 10:00pm

ASCO Gastrointestinal Cancers Symposium

The use of a minimally invasive procedure — known as trans-arterial chemoembolization — plus Lenvima and a PD-1 checkpoint blockade drug proved to be safe and efficacious in patients with unresectable advanced liver cancer.

Enhertu Linked to Sustained Survival Benefit in Gastroesophageal, Gastric Cancer Subset

Enhertu Linked to Sustained Survival Benefit in Gastroesophageal, Gastric Cancer Subset

January 21st 2022, 2:00pm

ASCO Gastrointestinal Cancers Symposium

The use of Enhertu was associated with a reduction in the risk of death compared with standard chemotherapy in certain patients with gastroesophageal and gastric cancer.

Keytruda/Chemo Combo Is ‘Great News’ for Patients With TNBC, ‘But We Need Much More’

Keytruda/Chemo Combo Is ‘Great News’ for Patients With TNBC, ‘But We Need Much More’

January 6th 2022, 2:00pm

SABCS

An expert discusses improvements in survival outcomes for patients with triple-negative breast cancer who received Keytruda plus chemotherapy — now considered the standard of care — but urges that more researched is always needed for this patient population.

Aromatase Inhibitors Reduce Recurrence Risk, But Not Death Rates, in Premenopausal Patients With Breast Cancer

Aromatase Inhibitors Reduce Recurrence Risk, But Not Death Rates, in Premenopausal Patients With Breast Cancer

January 5th 2022, 8:15pm

SABCS

Premenopausal women with ER-positive breast cancer experienced a decreased rate of recurrence when given an aromatase inhibitor, compared with those given tamoxifen. However, more research is still needed, an expert said.

Upfront Darzalex Combo May Be More Beneficial in the First-Line Setting for Transplant-Ineligible Myeloma Than Alternatives

Upfront Darzalex Combo May Be More Beneficial in the First-Line Setting for Transplant-Ineligible Myeloma Than Alternatives

January 5th 2022, 5:00pm

American Society of Hematology Annual Meeting

An expert from the Mayo Clinic explained that the use of a combination of drugs including Darzalex in the first-line setting may lead to better outcomes for patients with multiple myeloma instead of other first-line standard-of-care options.

Novel Drug Combo Induces Encouraging Results in Patients With Heavily Pretreated Breast Cancer

Novel Drug Combo Induces Encouraging Results in Patients With Heavily Pretreated Breast Cancer

January 3rd 2022, 10:00pm

SABCS

The use of Faslodex plus the investigational drug samuraciclib was considered safe in individuals with heavily pretreated hormone receptor-positive breast cancer.